Pasireotide in Hyperinsulinemic Hypoglycemia

• Status: Withdrawn
• Trial end date: 2018-04-01

Summary

This is a small controlled pilot study to assess the effect of subcutaneous pasireotide on preventing hypoglycemia due to hyperinsulinism, including congenital hyperinsulinism and insulinoma.

• Phase: Phase 2

Details

• Lead Sponsor: Montefiore Medical Center
• Collaborator: Novartis Pharmaceuticals
• Treatments: Pasireotide; Pharmaceutical Solutions; Somatostatin